<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004415</url>
  </required_header>
  <id_info>
    <org_study_id>AT-03A-006</org_study_id>
    <nct_id>NCT05004415</nct_id>
  </id_info>
  <brief_title>Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-AT-527 in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mass balance study of AT-527 in Healthy Male Subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-dose study assessing the absorption, metabolism, excretion, and&#xD;
      mass balance of [14C]-AT-527 in healthy adult male subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label, Single-Dose pharmacokinetic (PK) study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Total radioactivity recovery in urine and feces</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Percent of radioactive dose excreted in urine and feces</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>AT-527 550 mg (R07496998)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527 (R07496998)</intervention_name>
    <description>Study participants will receive a single radiolabeled dose of 550 mg AT-527.</description>
    <arm_group_label>AT-527 550 mg (R07496998)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2&#xD;
&#xD;
          -  No clinically significant diseases captured in the medical history or clinically&#xD;
             significant findings at screening physical examination.&#xD;
&#xD;
          -  A non-vasectomized, male subject must agree to use a condom with spermicide or abstain&#xD;
             from sexual intercourse during the study until 90 days after dosing. (No restrictions&#xD;
             are required for a vasectomized male provided his vasectomy has been performed 4&#xD;
             months or more prior to dosing. A male who has been vasectomized less than 4 months&#xD;
             prior to dosing must follow the same restrictions as a non-vasectomized male).&#xD;
&#xD;
          -  Willing to comply with the study requirements and to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Use of other investigational drugs within 28 days of dosing&#xD;
&#xD;
          -  Other clinically significant medical conditions or laboratory abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy, adult male, 19-55 years of age, inclusive, at the screening visit.</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>888-481-1607</phone>
    <email>AteaClinicalTrials@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

